Why Is Viking Therapeutics Stock Rising Today? Viking Therapeutics shares are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings and provided updates on clinical trials.
Viking Bolts Higher On 'Lightning' Speed Enrollment In Obesity Studies Viking Therapeutics stock popped Thursday on the lightening pace it's enrolling patients in a pair of obesity treatment tests.
Viking Therapeutics (NASDAQ:VKTX) Reports Q3 2025 Earnings Miss and 2.8% After-Hours Decline Viking Therapeutics Q3 2025 results show an earnings miss, with shares falling. The company's key Phase 3 obesity trial remains on track.
Retail Investors' Top Stocks With Earnings This Week: Tesla, Netflix, Intel and More Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck.
These 3 Obesity Drug Stocks Are Set to Soar This Fall and Beyond These companies are jockeying for position in a potential $150 billion market opportunity.
Did Viking Therapeutics Just Say "Checkmate" to Eli Lilly? The smaller drugmaker is looking to disrupt a fast-growing market.
Down 44%, Should You Buy the Dip on Viking Therapeutics? The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.
4 Healthcare Stocks to Buy Now As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.
Why Shares in Viking Therapeutics Surged This Week The small-cap pharmaceutical company may be the next in line as takeover fever heats up.
The Best Stocks to Invest $1,000 in Right Now Buying these three stocks offers you instant diversification.
Why This Beaten-Down GLP-1 Stock Could Be a Steal There's more to this company than its performance on the stock market this year suggests.
Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (
NYSE: LLY ) firmly at the forefront. What was once a niche segment has exploded into a multi-billion-dollar arena, driven by highly effective new medications, primarily GLP-1 receptor agonists, that are
Prediction: Viking Therapeutics Stock Will Double in Value Within the Next 12 Months Viking's stock took a beating last month, and it has opened up a glorious buying opportunity for investors.
